Company Overview
Catheter Precision, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it designs, manufactures, and sells medical technologies for cardiac electrophysiology in the United States. The company's primary business activity centers on providing non-invasive imaging systems, such as the View into Ventricular Onset System, which delivers 3D cardiac mapping capabilities to assist in localizing cardiac issues. This specialized operation supports the broader medical device ecosystem by offering tools that facilitate precise diagnostic procedures in electrophysiology. In terms of scale, the company carries a market capitalization of $2.57M and reports annual revenue of $730,000, supported by a workforce of 22 employees. These valuation and revenue figures indicate that Catheter Precision, Inc. functions as a micro-cap entity with limited market presence, suggesting a small-scale operational footprint relative to larger peers in the medical technology space. The low revenue base combined with a minimal employee count underscores the early-stage or niche nature of its current market position, where survival and unit economics are critical for future expansion.
Financial Health
The financial statements reveal a revenue of $730,000 over the trailing twelve months, yet this generates a net income of $-22,191,000 and an EBITDA of $-10,247,000. The substantial negative gap between the positive revenue of $730,000 and the deeply negative net income of $-22,191,000 reveals a cost structure where expenses significantly exceed gross profits, likely due to high R&D or administrative costs typical of small-cap medical device firms. Free cash flow stands at $-2,749,000, which indicates that the company is burning cash and lacks the immediate financial flexibility to fund operations without external capital infusion. The gross margin is reported at 92.6%, indicating highly efficient production costs relative to the sale price of the medical technologies, while the operating margin of -1336.7% and profit margin of 0.0% reflect severe losses on a per-revenue-dollar basis driven by high fixed costs. On the balance sheet, the company holds $2.06M in cash against $1.78M in debt, resulting in a debt-to-equity ratio of 27.68, which suggests a leveraged position where equity is minimal relative to the debt load. The current ratio of 0.46 indicates that current liabilities exceed current assets, signaling potential short-term liquidity challenges where the company may struggle to meet obligations as they come due. Furthermore, the return on equity is -181.3% and the return on assets is -29.6%, metrics that reveal management has not yet generated positive returns on the capital invested in the business or the assets utilized.
Valuation Assessment
Valuation metrics for Catheter Precision, Inc. present a complex picture, with a trailing P/E ratio of 0.03 and a forward P/E of -0.29. The discrepancy between a near-zero trailing P/E and a negative forward P/E implies that the market expects earnings to remain negative or deteriorate in the coming periods, preventing any meaningful earnings-based valuation. The price-to-book ratio is 0.26, indicating that the market values the company at roughly a quarter of its book value, which often suggests the market perceives significant intangible risks or expects that the company's assets are overvalued on the books. Alternative metrics show a price-to-sales ratio of 3.52 and an EV/EBITDA of -0.12, suggesting that the market is pricing the stock based on revenue multiples rather than earnings power due to the lack of profitability. Regarding trading ranges, the stock has a 52-week high of $15.77 and a 52-week low of $1.05, meaning the current price sits somewhere within this wide volatility band, though the exact percentage distance from the high or low requires the specific current share price which is not explicitly listed in the provided facts. The beta value is -0.16, which is an anomalous figure for equities, suggesting an inverse correlation to the broader market or significant volatility that deviates from standard market movements.
Growth & Income
The company demonstrates robust top-line momentum with revenue growth of 135.4% year-over-year, whereas earnings growth is marked as N/A due to the lack of profitable earnings to measure. Since there are no earnings to grow, the revenue expansion does not translate into earnings growth in the traditional sense, implying that the rapid top-line increase is currently being consumed by high operating expenses rather than bottom-line accretion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all available cash to reinvest into product development or to service its debt obligations. This non-dividend profile is consistent with a growth-stage company that prioritizes capital allocation toward operational scaling over income distribution to shareholders. Consequently, the overall growth and income profile is characterized by high revenue expansion coupled with significant cash burn and a complete absence of shareholder returns through dividends or earnings growth.